Novo Nordisk Slashes Ozempic and Wegovy Prices in India to Combat Generic Competition

Danish pharmaceutical giant Novo Nordisk has announced significant price reductions for its flagship diabetes and weight-loss drugs in the Indian market. The company slashed the price of Ozempic by 36% and Wegovy by 48% as it faces an influx of low-cost generic alternatives from local manufacturers. This strategic move aims to defend Novo Nordisk's market share in one of the world's fastest-growing healthcare markets. Analysts note that while the price cuts will help maintain sales volume, they signal increasing margin pressure on the company's blockbuster semaglutide products. The entry of cheaper generic versions has effectively ended the firm's exclusive pricing power in the region. Investors are closely monitoring how these adjustments will impact the company's long-term profitability in emerging markets.